Caterina Sposetti, Medical Oncology Fellow at Dana-Farber’s Breast Oncology Center and Dana-Farber Zakim Center, posted on X:
“Dr. Ligibel summarizes the significant impact of a weight loss intervention on key metabolic biomarkers, i.e. leptin, insulin, CRP, insulin resistance (HOMA) in the phase III BWEL study (n=3,181), elegantly presented at SABCS 2024.”
